NewAmsterdam Current Deferred Revenue from 2010 to 2025
| NAMS Stock | 21.00 0.09 0.43% |
Current Deferred Revenue | First Reported 2010-12-31 | Previous Quarter 6 M | Current Value 8.7 M | Quarterly Volatility 2.8 M |
Check NewAmsterdam Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NewAmsterdam Pharma's main balance sheet or income statement drivers, such as Net Interest Income of 17.7 M, Interest Income of 17.7 M or Depreciation And Amortization of 59.2 K, as well as many indicators such as Price To Sales Ratio of 33.94, Dividend Yield of 0.0 or PTB Ratio of 3.36. NewAmsterdam financial statements analysis is a perfect complement when working with NewAmsterdam Pharma Valuation or Volatility modules.
NewAmsterdam | Current Deferred Revenue |
Latest NewAmsterdam Pharma's Current Deferred Revenue Growth Pattern
Below is the plot of the Current Deferred Revenue of NewAmsterdam Pharma over the last few years. It is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. NewAmsterdam Pharma's Current Deferred Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in NewAmsterdam Pharma's overall financial position and show how it may be relating to other accounts over time.
| Current Deferred Revenue | 10 Years Trend |
|
Current Deferred Revenue |
| Timeline |
NewAmsterdam Current Deferred Revenue Regression Statistics
| Arithmetic Mean | 4,995,148 | |
| Geometric Mean | 4,511,196 | |
| Coefficient Of Variation | 56.03 | |
| Mean Deviation | 2,082,223 | |
| Median | 3,607,000 | |
| Standard Deviation | 2,798,972 | |
| Sample Variance | 7.8T | |
| Range | 9.4M | |
| R-Value | 0.63 | |
| Mean Square Error | 5.1T | |
| R-Squared | 0.39 | |
| Significance | 0.01 | |
| Slope | 368,541 | |
| Total Sum of Squares | 117.5T |
NewAmsterdam Current Deferred Revenue History
About NewAmsterdam Pharma Financial Statements
NewAmsterdam Pharma shareholders use historical fundamental indicators, such as Current Deferred Revenue, to determine how well the company is positioned to perform in the future. Although NewAmsterdam Pharma investors may analyze each financial statement separately, they are all interrelated. The changes in NewAmsterdam Pharma's assets and liabilities, for example, are also reflected in the revenues and expenses on on NewAmsterdam Pharma's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 6 M | 8.7 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for NewAmsterdam Stock Analysis
When running NewAmsterdam Pharma's price analysis, check to measure NewAmsterdam Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NewAmsterdam Pharma is operating at the current time. Most of NewAmsterdam Pharma's value examination focuses on studying past and present price action to predict the probability of NewAmsterdam Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NewAmsterdam Pharma's price. Additionally, you may evaluate how the addition of NewAmsterdam Pharma to your portfolios can decrease your overall portfolio volatility.